Skip to Content
  • Revenues ($M)$32,639
  • Revenue Percent Change31.1%
  • Profits ($M)$18,108
  • Profits Percent Change49.6%
  • Assets ($M)$51,839
  • Employees8,000
  • Market Value — as of March 31, 2016 ($M)$124,437
  • Previous Rank118
  • Morning Consult Brand Index
    D

The California-based biotech continued its rocket-like ascent in 2015–just two years ago it ranked No. 250 on the 500–due to booming sales of its breakthrough Hepatitis C medications. Those drugs–Sovaldi and Harvoni–which cost a fortune, but also cure a chronic, devastating disease, sparked a national debate on drug pricing. They also drove Gilead’s bottom and top lines in 2015–revenues and profits jumped 31% and 50%, respectively. John Milligan, Gilead’s new CEO faces rockier road in 2016: the competition is stiffer and IP challenges and pricing pressures loom.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Info

CEO
John F. Milligan
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
Foster City, CA
Websitehttp://www.gilead.com
Years on Fortune 500 List8
Employees8,000

Key Financials (last fiscal year)

$ millions% change
Revenues ($M)$32,63931.1%
Profits ($M)$18,10849.6%
Assets ($M)$51,839-
Total Stockholder Equity ($M)$18,534-
Market Value — as of March 31, 2016 ($M)$124,437-

Profit Ratios

Profit as % of Revenues55.5%
Profits as % of Assets34.9%
Profits as % of Stockholder Equity97.7%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)11.91
EPS % Change (from 2014)62%
EPS % Change (5 year annual rate)48.3%
EPS % Change (10 year annual rate)39.4%

Total Return

Total Return to Investors (2015)8.7%
Total Return to Investors (5 year, annualized)41.4%
Total Return to Investors (10 year, annualized)22.8%